Group 1 - The core focus of the recent news is on the strategic cooperation and governance changes of China National Pharmaceutical Group (08247.HK) [1] - On February 11, 2026, the company signed a strategic cooperation agreement with Guangdong Xiaoshou Medical Technology Co., Ltd., aiming to enhance collaboration in grassroots medical services [1] - The company completed a board restructuring on February 9, 2026, with Chen Peng appointed as the new chairman, while Chen Zhengyong remains an executive director [1] Group 2 - Following these events, the company's stock price exhibited a volatile upward trend, opening at HKD 4.85 on February 9 and reaching a peak of HKD 5.16 on February 11, marking a maximum increase of 6.46% [2] - As of February 13, 2026, the stock price was reported at HKD 4.92, reflecting a daily decline of 0.61%, but a cumulative increase of 2.50% over the past five days and a year-to-date increase of 117.70% [2] - Trading volume peaked at 108,000 shares on the day of the cooperation announcement, indicating high market interest, but subsequently decreased to 14,000 shares by February 13, suggesting a consolidation phase [2]
中生北控生物科技签署战略合作协议并完成董事会换届